Role of pioglitazone in the prevention of restenosis and need for revascularization after bare-metal stent implantation: A meta-analysis

JACC: Cardiovascular Interventions

Volumn 4, Issue 3, 2011, Pages 353-360

  Patel, Dhavalkumar ^a   Walitt, Brian ^a   Lindsay, Joseph ^a   Wilensky, Robert L ^b  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

neointima; pioglitazone; restenosis; revascularization

Indexed keywords

CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; TRIACYLGLYCEROL;

AGE; ANGIOGRAPHY; ARTERY DIAMETER; ARTICLE; BARE METAL STENT; BLOOD PRESSURE; BODY MASS; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIABETIC PATIENT; DRUG EFFECT; FOLLOW UP; GENDER; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPERTENSION; IN-STENT RESTENOSIS; INTRAVASCULAR ULTRASOUND; META ANALYSIS; MORTALITY; NEOINTIMA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PREMEDICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVASCULARIZATION; SMOKING; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY STENOSIS; DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; HUMANS; HYPOGLYCEMIC AGENTS; METALS; MIDDLE AGED; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; STENTS; THIAZOLIDINEDIONES; TIME FACTORS; TREATMENT OUTCOME;

EID: 79953000587     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2010.10.016     Document Type: Article

References (36)

1. G.W. Stone, S.G. Ellis, and D.A. Cox A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease N Engl J Med 350 2004 221 231 (Pubitemid 38067635)
2. A.A. Bavry, D.J. Kumbhani, T.J. Helton, P.P. Borek, G.R. Mood, and D.L. Bhatt Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials Am J Med 119 2006 1056 1061 (Pubitemid 44826931)
3. B. Lagerqvist, S.K. James, and U. Stenestrand Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden N Engl J Med 356 2007 1009 1019 (Pubitemid 46376801)
4. R. Kornowski, G.S. Mintz, and K.M. Kent Increase restenosis in diabetes mellitus after coronary interventions is due to exaggerated neointimal hyperplasia: a serial intravascular ultrasound study Circulation 95 1997 1366 1379
5. A. Kastrati, A. Schmig, and S. Elezi Predictive factors of restenosis after coronary stent placement J Am Coll Cardiol 30 1997 1428 1436 (Pubitemid 27486458)
6. S.J. Hong, M.H. Kim, and T.H. Ahn Multiple predictors of coronary restenosis after drug-eluting stent implantation in patients with diabetes Heart 92 2006 1119 1124 (Pubitemid 44125234)
7. H. Yki-Jrvinen Thiazolidinedione N Engl J Med 351 2004 1106 1118
8. S.E. Nissen, and K. Wolski Effect of rosiglitazone on death and major adverse cardiovascular events in patient with type 2 diabetes mellitus N Engl J Med 356 2007 2457 2471
9. A. Hsiao, D.S. Worrall, J.M. Olefsky, and S. Subramaniam Variance-modeled posterior inference of microarray data: detecting gene-expression changes in 3T3-L1 adipocytes Bioinformatics 20 2004 3108 3127 (Pubitemid 39619201)
10. R.B. Goldberg, D.M. Kendall, and M.A. Deeg A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia Diabetes Care 28 2005 1547 1554 (Pubitemid 40923063)
11. A.M. Lincoff, K. Wolski, and S.J. Nicholls Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials JAMA 298 2007 1180 1188 (Pubitemid 47403104)
12. R. Rajagopalan, Y. Xu, M. Abbadessa Quartet Study Group The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials Am J Geriatr Pharmacother 4 2006 123 133 (Pubitemid 44069474)
13. C. Clar, P. Royle, and N. Waugh Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis PLoS One 4 2009 e6112
14. N. Marx, H. Duez, J.C. Fruchart, and B. Staels Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells Circ Res 94 2004 1168 1178 (Pubitemid 38656403)
15. A. Pftzner, N. Marx, and G. Lbben Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study J Am Coll Cardiol 45 2005 1925 1931 (Pubitemid 40814110)
16. T. Takagi, H. Okura, and Y. Kobayashi A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study) J Am Coll Cardiol Intv 2 2009 524 531
17. H. Kaneda, T. Shiono, and Y. Miyashita Efficacy and safety of pioglitazone in patients with ST elevation myocardial infarction treated with primary stent implantation Heart 95 2009 1079 1084
18. T. Katayama, H. Ueba, and K. Tsuboi Reduction of neointimal hyperplasia after coronary stenting by pioglitazone in nondiabetic patients with metabolic syndrome Am Heart J 153 2007 e1 e7
19. K. Nishio, M. Sakurai, and T. Kusuyama A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes Diabetes Care 29 2006 101 106 (Pubitemid 44033439)
20. N. Marx, J. Whrle, and T. Nusser Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients Circulation 112 2005 2792 2798 (Pubitemid 41641673)
21. T. Takagi, A. Yamamuro, and K. Tamita Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study Am Heart J 146 2003 E5
22. R. Pakala, C. Dilcher, and R. Baffour Peroxisome proliferator-activated receptor y ligand pioglitazone alters neointimal composition in a balloon-denuded and radiated hypercholesterolemic rabbit J Cardiovasc Pharmacol 48 2006 299 305 (Pubitemid 46066835)
23. M. Joner, A. Farb, and Q. Cheng Pioglitazone inhibits in-stent restenosis in atherosclerotic rabbits by targeting transforming growth factor-B and MCP-1 Arteriosclerosis 27 2007 182 189 (Pubitemid 46360397)
24. T. Kasai, K. Miyauchi, and T. Yokoyama Pioglitazone attenuates neointimal thickening via suppression of early inflammatory response in a porcine coronary after stenting Atherosclerosis 197 2008 612 619 (Pubitemid 351417907)
25. E.S. Rosmarakis, and M.E. Falagas Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: a meta-analysis of randomized controlled trials Am Heart J 154 2007 144 150 (Pubitemid 46920490)
26. D.F. Geng, D.M. Jin, W. Wu, Z. Wang, and J.F. Wang Effect of thiazolidinediones on in-stent restenosis in patients after coronary stenting: a meta-analysis of randomized controlled trials Atherosclerosis 202 2009 521 528
27. A.R. Jadad, R.A. Moore, and D. Carroll Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1996 1 12 (Pubitemid 26120810)
28. J.P. Little, N. Osman, S.T. de Dios, N. Cemerlang, M. Ballinger, and J. Nigro Anti-proliferative activity of oral anti-hyperglycemic agents on human vascular smooth muscle cells: thiazolidinediones (glitazones) have enhanced activity under high glucose conditions Cadiovasc Diabetol 6 2007 33
29. C.V. Desouza, M. Gerety, and F.G. Hamel Long term effect of a PPAR-gamma agonist, pioglitazone, on neointimal hyperplasia and endothelial regrowth in insulin resistant rats Vasc Pharmacol 46 2006 188 194 (Pubitemid 46096813)
30. Y. Aizawa, J. Kawabe, N. Hasebe, N. Takehara, and K. Kikuchi Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduced intimal hyperplasia Circulation 104 2001 455 460 (Pubitemid 32678277)
31. R. Komastu, M. Ueda, T. Naruko, A. Kojima, and A.E. Becker Neointimal tissue response at sites of coronary stenting in humans; microscopic, histological and immunohistochemical analyses Circulation 98 1998 224 233 (Pubitemid 28337613)
32. D. Li, K. Chen, and N. Sinha The effect of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation Cardiovasc Res 65 2005 907 912 (Pubitemid 40253577)
33. M. Komajda, J.J. McMurray, and H. Beck-Nielsen Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial Eur Heart J 31 2010 824 831
34. J.A. Dormandy, B. Charbonnel, and D.J. Eckland Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study: a randomised controlled trial Lancet 366 2005 1279 1289
35. S.E. Nissen, S.J. Nicholls, and K. Wolski Comparison of pioglitazone vs glimeperide on progression of coronary atherosclerosis in the patient with type 2 diabetes: the PERISCOPE randomized controlled trial JAMA 299 2008 1561 1571
36. G. Chinetti, S. Lestavel, and V. Bocher PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway Nat Med 7 2001 53 58 (Pubitemid 32095642)